Hepatectomy for liver metastases from gastric cancer: a systematic review by unknown
RESEARCH ARTICLE Open Access
Hepatectomy for liver metastases from
gastric cancer: a systematic review
Ying-Yang Liao1†, Ning-Fu Peng2†, Di Long3, Peng-Cheng Yu3, Sen Zhang3, Jian-Hong Zhong2* and Le-Qun Li2
Abstract
Background: Official guidelines recommend palliative treatments for patients with liver metastases from gastric
cancer. However, many case series reported that hepatectomy for such cases is safe and effective. This systematic
review compares the overall survival between hepatectomy and palliative therapy in patients with liver metastases
from gastric cancer.
Methods: Two independent reviewers performed a systematic search of literature in EMBASE and PubMed,
updated until 26 October 2016. The Newcastle-Ottawa score for cohort studies was used for quality assessment of
included studies.
Results: A total of eight cohort studies involving 196 patients in the hepatectomy arm and 481 in the palliative
arm were included. Median overall survival of patients in the two arms was 23.7 (range, 13.0 to 48.0) and 7.6 (range,
5.5 to 15.2), respectively. Median rates of overall survival of the two arms were 69, 40, 33 and 27, 8, 4% at 1, 2, and
3 years, respectively. Comparing with palliative therapy, hepatectomy was associated with significantly lower
mortality at 1 year (odds ratio 0.17, P < 0.001) and 2 years (odds ratio 0.15, P < 0.001). Among the patients who
underwent hepatectomy, Asian cohorts showed higher median rates of overall survival than Western cohorts at
1 year (76 vs. 60%), 2 years (47 vs. 30%) and 3 years (39 vs. 23%).
Conclusions: Hepatectomy in the management of liver metastases from gastric cancer can be considered effective.
In the elective setting, hepatectomy provides a potential alternative to palliative therapy.
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Background
As the sixth highest incidence and the second leading
cause of cancer deaths worldwide, gastric cancer is the
most common form of cancer, with more than 951,000
new cases worldwide diagnosed in 2012 [1]. Due to late
onset and nonspecific symptoms, the majority of gastric
cancer cases present in advanced stage, with less than
30% of patients eligible for curative resection [2]. In
recent decade, treatment of gastric cancer has been
significantly improved, and the 5-year overall survival of
patients with T1 tumors is up to 95% [3]. However, the
prognoses of patients represented by peritoneal or liver
metastases is extremely poor, with a 3-year overall
survival lower than 10% after chemotherapy [4, 5].
Gastrectomy is more used in Eastern centers than
Western centers. And Eastern patients’ prognoses after
gastrectomy are better than those in Western [6].
According to the guideline of the Japanese Classification
of Gastric Carcinoma [7], liver metastases from gastric
cancer is categorized as stage IV disease. This guideline
[7] and the National Comprehensive Cancer Network
guideline [8, 9] do not recommend surgery for stage IV
gastric cancer, which lead to most patients with liver
metastases of gastric cancer receive palliative treatment
(such as chemotherapy). Though the necessity of
hepatectomy for liver metastases of gastric cancer is still
controversial, the Guidelines Committee of the Japan
Gastric Cancer Association reconsidered the treatment




2Hepatobiliary Surgery Department, Affiliated Tumor Hospital of Guangxi
Medical University, Nanning 530021, Guangxi Province, China
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Liao et al. BMC Surgery  (2017) 17:14 
DOI 10.1186/s12893-017-0215-0
Recently, many case-control or case series studies of
liver metastases from gastric cancer have been reported.
However, most of these studies are presented from a
single center, have a small sample size, and/or include
old cases from the 1960s and 1980s [11–20]. Therefore,
it is important to thoroughly analyze the significance
of hepatectomy for liver metastases from gastric can-
cer, and compare the efficacy of hepatectomy with
palliative therapy for such patients in recent two de-
cades (1990–2016) with a systematic review.
Methods
Two independent authors performed a systematic review
(Y.-Y.L, D.L) according to the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
statement [21]. A study protocol was followed which de-
fined the study objectives, eligibility criteria, outcome
measures, search strategy and methodology of analysis.
The quality of included studies was assessed using the
Newcastle-Ottawa score for cohort studies [22]. This
tool was chosen because of the unavailability of random-
ized controlled trials and large heterogeneity between
studies.
Search strategy
A systematic search of literature, updated until 26
October 2016, was performed by two independent re-
viewers (Y.-Y.L, D.L). The EMBASE and PubMed da-
tabases were searched using MeSH and free text
words. MeSH and free text words concerning gastric
cancer and metastasis were used. No language or time
period restrictions were applied. Titles and abstracts
retrieved from the search were screened for relevance
and selected studies. Disagreements during the search
and selection process were resolved by discussion
and, if needed, a third reviewer (N.-F.P) was
consulted to reach consensus. Reference lists of all in-
cluded articles were screened for additional eligible
papers.
The following search strategy was used in PubMed
(Medline):
((“cancer” [Mesh] AND “gastric Neoplasms” [Mesh])
OR “neoplasm, stomach” [Mesh] OR stomach
neoplasm*[tw] OR gastric neoplasm*[tw] OR cancer of
stomach*[tw] OR stomach cancer*[tw] OR gastric can-
cer*[tw]) AND (“Metastases, Neoplasm” [Mesh] OR
metastasis*[tw] OR metastases*[tw]) AND (surgery*[tw]
OR resection*[tw] OR hepatectomy*[tw]) AND (hepa-
tic*[tw] OR liver*[tw]).
Eligibility criteria and data extraction
Criteria for final study inclusion were: (1) study popula-
tion formed by patients with liver metastases from gas-
tric cancer in the absence of peritoneal metastasis or
extractable from studies in which hepatectomy was per-
formed; (2) sufficient description of the study popula-
tion; (3) description of patient survival rates for at least
1 year after hepatectomy; (4) the study had a random-
ized control, cohort, or case-control design. In order to
reduce the bias of diagnosis, original treatments, neoad-
juvant and adjvuant treatments, only cases after 1990
may be included. In cases in which a study was followed
by a more complete study or studies that included the
original data set, the most recent and complete report
was chosen. Such linked studies were identified on the
grounds of authorship, institutions, design, length of
follow-up, and study populations. If additional data or
results were needed, the corresponding author of each
report was contacted by e-mail.
Data were extracted by two authors (Y.-Y.L, D.L) using
standardized forms. The following data were collected:
author details, country, recruitment period, study design,
median follow-up, sample size, gender, positive and
negative findings, and methodological quality. A third
author (N.-F.P) checked the extracted data against the
original studies. Survival data were taken directly from
tables or the text whenever possible; if such data were
presented only in graphs, they were extracted by manual
interpolation. P values associated with inter-group differ-
ences in mortality were extracted directly from survival
curves, text, or tables wherever possible.
Statistical analysis
Meta-analysis was performed on an intention-to-treat
basis. To assess attrition bias, we calculated mortality
using a ‘worst-case’ approach in which patients with
missing data were counted as treatment failures (death).
For patients with missing data, we ’carried forward’ data
from the most recent measurement.
Outcomes are displayed as they were reported in the ori-
ginal article. All statistical tests for this meta-analysis were
performed using Stata 11.0 softwares. Due to the high likeli-
hood of mortality, odds ratio (ORs) with corresponding 95%
confidence intervals (95% CIs) were calculated for dichot-
omous outcomes using the Mantel-Haenszel method. Point
estimates of RR were considered statistically significant
when P < 0.05. Statistical heterogeneity was explored by in-
consistency (I2) statistics; in particular, I2 values of <25% was
interpreted as low heterogeneity, between 25 and 50% as
medium, between 50 and 75% as substantial and above 75%
as considerable [23].
Results
A total of 3629 records were identified. Following
screening for duplications, 2108 articles remained. After
screening by title and abstract, a further 2057 records
were excluded. Of the remaining 52 articles which need
full-text assessment, 35 were studies with single arm
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investigating the role of hepatectomy for liver metastases
from gastric cancer [11–20, 24–48]. In the end, only 8
studies compared the efficacy of hepatectomy to that of
other palliative treatments met the eligibility criteria and
were included in a quantitative synthesis [49–56]. Details
are listed in Fig. 1.
Baseline characteristics
Five of the studies based on Eastern population [49, 50,
52, 53, 56] while the other three based on Western
population [51, 54, 55]. These eight studies included 196
patients in the hepatectomy arm and 481 in the pallia-
tive arm. Most patients in the hepatectomy arm (70%)
underwent minor hepatectomy. No study described
complications during or after hepatectomy. Patient
demographics and characteristics of liver metastases
from gastric cancer are summarized in Table 1. The
median follow-up was 13.2 months.
Efficacy
Median overall survival of patients in the hepatectomy
arm and those in the palliative arm was 23.7 (range, 13.0
to 48.0) and 7.6 (range, 5.5 to 15.2), respectively. Median
rates of overall survival of the two arms were 69, 40, 33
and 27, 8, 4% at 1, 2, and 3 years, respectively (Table 2).
Comparing with palliative therapy, hepatectomy was
associated with significantly lower mortality at 1 year
(OR 0.17, 95% CI 0.11–0.26, P < 0.001; Fig. 2) and 2 years
(OR 0.15, 95% CI 0.09–0.25, P < 0.001; Fig. 3).
Among the patients who underwent hepatectomy, com-
parison of studies performed in Asian countries (5 studies,
117 patients) and Western countries (3 studies, 79 pa-
tients) indicated that Asian cohorts showed higher median
rates of overall survival at 1 year (76 vs. 60%), 2 years (47
vs. 30%) and 3 years (39 vs. 23%).
Quality assessment
Details on individual quality of studies are displayed in
Table 3. Among the 8 cohort studies, only one had eight
stars [50], one had seven stars [52], and the remaining 6
studies had six stars [49, 51, 53–56].
Discussion
Among all included studies in this systematic review, a
total of 196 patients were treated with hepatectomy for
liver metastases from gastric cancer. Hepatectomy was
associated significantly better overall survival than
palliative therapy for such patients. Our results were
consistent with previous reviews [57–60].
The liver is a common site of distant metastasis from
gastrointestinal tract cancer, including gastric cancer.
Hepatectomy is now widely accepted as a potentially
curative treatment for hepatocellular carcinoma [61, 62]
and colorectal liver metastases [63], with reported 5-year
overall survival of 40–50% [61–63]. Moreover, indica-
tions of hepatectomy for hepatocellular carcinoma and
colorectal liver metastases have been expanded by pro-
gress in surgical procedures, perioperative care and/or
chemotherapy. Liver metastases from gastric cancer not
only show more aggressive oncological behavior and het-
erogeneous characteristics, but also are with frequently
other metastatic extrahepatic lesions, such as peritoneal
seeding or extensive lymph node metastases, leading to
a dismal prognosis and debatable benefits of hepatec-
tomy. Therefore, chemotherapy is regarded as the first-
choice treatment in most guidelines. However, a lot of
case reports and case series supported the role of hepa-
tectomy for liver metastases from gastric cancer [11–20,
24–48], which lead to Japanese guideline reconsidered
the role of hepatecotmy for such patients [10].
Previous systematic reviews [57–60] were mainly
based on some part of the case series [11–20, 24–48].
Many of the quoted and included studies of these sys-
tematic reviews are of small studies stretching back in
some cases to the 1960’s. This leads to many concerns
over the diagnosis, original treatments, neoadjuvant and
adjuvant treatments in such a big time span. Assessment
of metastatic disease in the pre multilevel computer
tomography and positron emission tomography era is
also doubtful when trying to compare outcomes. In
addition, those systematic reviews are not comparing
like with like. Those undergoing hepatectomy are a
highly selected group with resectable liver disease in the
Fig. 1 Flow chart of study selection
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absence of other disease. It is not reasonable to compare
this with all comers with widespread metastatic disease.
It would be more reasonable to cone in on those studies
where comparative outcomes were considered. There-
fore, we only focus on cohort studies which comparing
hepatectomy and palliative therapy and patients who
were included after 1990. Such results may be more
reliable than previous.
Our systematic review revealed that median overall
survival after hepatectomy was 23.7 (range, 13.0 to 48.0).
Median overall survival was ranges from 24 to
40.8 months after hepatectomy among other large scale
case series (>60 cases) [40, 46–48]. Hepatectomy for
liver metastases from gastric cancer is not performed
frequently at present. It is notable that none of the
patients who underwent hepatectomy in this systematic
review or these case series [40, 46–48] was with periton-
eal metastasis. Careful patient selection is likely to be
important for ensuring good prognosis after hepatec-
tomy. The number of hepatic tumors (≥3), tumor diam-
eter (≥5), and serosal invasion of the primary tumor
were identified as prognostic factors associated with a
poor overall survival [19, 37, 40, 46]. Moreover, patients
with more risk factors have much poor survival rates at
3 or 5 years after hepatectomy [46]. Therefore, palliative
therapy should be considered when any of these factors
is recognized at diagnosis. Other indications for hepatec-
tomy included adequate physical condition, preserved
liver function, and feasibility of complete tumor resec-
tion. In addition, indications for hepatectomy may also
need to consider response rate to neoadjuvant chemo-
therapy in those patients who receive it, since prognosis
of non-responders is generally worse than that of
responders [64, 65].
The role of neoadjuvant or adjuvant therapy for liver
metastases from gastric cancer is still controversial. Of
the eight included studies, 16.4% patients received neo-
adjuvant therapy, while 55.2% received adjuvant therapy.
If all case series [11–20, 24–48] and these eight cohort
studies [49–56] were included into analysis, the percent-
age of patients who received neoadjuvant therapy for the
primary gastric cancer was 11.3%, and the percentage of
patients receiving adjuvant therapy was 55.1%. For pa-
tients with gastric cancer with extensive lymph node
metastasis, Tsuburaya and coworkers found neoadjuvant
chemotherapy with 4-weekly S-1 and cisplatin followed




















Chen 2013 China 2007–2012 20/94 10 57 12/8 8/12 11/9 20/0
Cheon 2008 Korea 1995–2005 41/17 16 60 34/7 28/13 NR 30/11
Dittmar 2012 Germany 1995–2009 15/83 11 57 12/3 8/7 12/3 9/6
Makino 2010 Japan 1992–2007 16/47 NR NA 13/3 9/7 11/5 9/7
Miki 2012 Japan 1995–2009 25/25 NR 72 23/2 18/7 20/5 16/9
Tiberio 2009 Italy 1990–2004 11/62 19 NR NR NR NR 0/11
Tiberio 2015 Italy 1997–2011 53/142 NR NR NR NR NR 53/0
Ueda 2009 Japan 1991–2005 15/11 NR NR NR NR NR NR
NR not reported
Table 2 Overall survival of patients with hepatic metastases from gastric cancer after hepatectomy or palliative treatments
Study Hepatectomy arm Palliative arm P
Median survival (moths) 1-year 2-year 3-year Median survival (moths) 1-year 2-year 3-year
Chen 2013 22.3 70 30 21 5.5 15 0 0 <0.001
Cheon 2008 18.3 75 38 32 8.1 29 0 0 <0.001
Dittmar 2012 48.0 79 64 55 9.0 42 18 9 <0.001
Makino 2010 38.2 87 68 56 15.2 53 12 4 <0.001
Miki 2012 33.4 74 55 43 8.7 40 18 18 0.045
Tiberio 2009 23.0 80 30 20 6.9 28 6 3 <0.001
Tiberio 2015 13.0 50 21 14 5.5 13 7 2 <0.001
Ueda 2009 - 80 60 60 10.0 36 0 0 <0.001
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by D2 gastrectomy is safe and effective for some patients
[66]. Further trials should be performed to investigate
the role of neoadjuvant therapy as a biological trial.
We found Asian cohorts showed higher median rates
of overall survival than Western cohorts. Western co-
horts usually show more advanced stage of disease than
Asian cohorts [19, 24, 28, 41, 43, 50, 51, 54, 55]. Such
presentation may lead to more Western cases receive
chemotherapy while more Asian cases receive curative
resection. Even so, there needs to be consideration of
the role of chemotherapy versus surgery in the chemo-
therapy naïve patients. In this systematic review, hepa-
tectomy associated with a median overall survival of
23.7 months. However, median overall survival was only
11.3 to 13.8 months after combination therapy with or
without trastuzumb for advanced gastric cancer [4, 67].
Therefore, our results suggest that hepatectomy is asso-
ciated with substantially longer median overall survival
than combination chemotherapy with or without
targeted therapy. In selected patients, hepatectomy may
be preferable to chemotherapy.
A limitation of our study is the low availability of high
level evidence studies in literature. Since all studies were
retrospective cohort studies, a potential bias is that the
positive effects of hepatectomy are overestimated, as
cases of unsuccessful resection are less likely to be re-
ported or published. Moreover, the types and frequency
of postoperative complications remain unclear because
all of the studies failed to report such data. Most pa-
tients underwent minor rather than major hepatectomy.
Heterogeneity in surgical technique and skill may also
affect patient prognosis.
Fig. 2 Meta-analysis of mortality at 1 year after hepatectomy or palliative therapies in patients treated for liver metastases from gastric cancer
Fig. 3 Meta-analysis of mortality at 2 years after hepatectomy or palliative therapies in patients treated for liver metastases from gastric cancer
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Conclusions
This systematic review provides comprehensive evidence
that hepatectomy is associated with longer median over-
all survival than palliative treatments for selected pa-
tients with liver metastases from gastric cancer. If our
findings can be verified and extended in a completion of
a randomized controlled trial on hepatectomy versus
chemotherapy or a high-quality prospective study with
long-term follow-up, they make a strong argument for
changing current clinical practices and official guidelines
to bring them into line with the evidence base.
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